TetraLogic Pharmaceuticals, which is developing small molecule therapeutics for the treatment of cancer, postponed its IPO on Thursday citing poor market conditions. The Malvern, PA-based company was founded in 2001. TetraLogic Pharmaceuticals initially filed confidentially on 9/16/2013. Oppenheimer & Co., Guggenheim Securities and Needham & Co. were set to be the joint bookrunners on the deal.
